A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.
Also called NCT06024746
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,500 participants
- Registry
-
NCT06024746
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, Canada, China, India, Spain, Sri Lanka, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06024746. Randomized; no masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2027-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
- Acronym
- CONFIRMATION
- Condition
- Heart Failure
- Intervention (Drug)
- Finerenone
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Colorado Prevention Center
- Collaborator
- Saint Luke's Mid America Heart Institute
- Collaborator
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Record details
- Record id
cardio:ct-nct06024746- Content hash
0c85a31c09b62f3dd471cd8b6c7dd3ad8182bc0aa7909d1e9ed8ca13934ba3dd